Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joung, Kyung-In | - |
dc.contributor.author | Song, Jong Hwa | - |
dc.contributor.author | Suh, Kangho | - |
dc.contributor.author | Lee, Seung-Mi | - |
dc.contributor.author | Jun, Ji Hyun | - |
dc.contributor.author | Park, Taehwan | - |
dc.contributor.author | Suh, Dong Churl | - |
dc.date.accessioned | 2022-01-20T02:40:43Z | - |
dc.date.available | 2022-01-20T02:40:43Z | - |
dc.date.issued | 2021-01 | - |
dc.identifier.issn | 1173-8804 | - |
dc.identifier.issn | 1179-190X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53946 | - |
dc.description.abstract | Background Recent studies have shown that treatment with the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor class could significantly improve survival outcomes in several oncology indications. However, there is some clinical uncertainty. Objective This study aimed to obtain high-level estimates of the impact of treatment with PD-1/PD-L1 inhibitor class to oncology treatment on key health outcomes in real-world situations and to inform public health policy decisions about cancer care after reducing uncertainties around new immuno-oncology therapy options in South Korea. Methods A model was developed to estimate the impact of PD-1/PD-L1 inhibitors on outcomes in situations wherein both anti-PD-1/PD-L1s and standard of care (SOC) were available versus SOC only. A partitioned survival model was utilized to estimate the impact of introducing anti-PD-1/PD-L1s on outcomes, including life-years gained, quality-adjusted life-years gained, progression-free survival-years obtained, and grade 3 or higher adverse events avoided for six indications over 5 years. An exponential distribution was fitted to the survival function of the SOC based on visual inspection. Outcomes associated with anti-PD-1/PD-L1s were estimated using a piecewise modeling approach with Kaplan-Meier analysis followed by best-fitting survival analysis. The incident number of patients and market share of anti-PD-1/PD-L1s during 2020-2024 were projected using published literature and Korean market survey data. Sensitivity analyses were performed to test the uncertainty of input parameters. Results During the next 5-year period (2020-2024), introducing the anti-PD-1/PD-L1 class led to a gain of 22,001 life-years (+ 31%), 19,073 quality-adjusted life-years (+ 38%), and 22,893 progression-free survival-years (+ 82%); it also avoided 3610 adverse events (- 11%) compared with SOC alone. Most adverse events associated with anti-PD-1/PD-L1s were attributed to combination therapy with cytotoxic chemotherapy (91%). In a scenario wherein the time to reimbursement of the anti-PD-1/PD-L1s was accelerated by 1 year, the life-years gained increased by 14% compared with the base-case scenario. Conclusions Anti-PD-1/PD-L1 therapy is expected to provide marked survival benefits for patients with cancer. This study demonstrated the potentially beneficial health impacts of utilizing the anti-PD-1/PD-L1 class at the population level. The findings could inform health policy decision makers about cancer care and ultimately enhance population health through rapid access to innovative cancer drugs. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ADIS INT LTD | - |
dc.title | Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s40259-020-00459-2 | - |
dc.identifier.bibliographicCitation | BIODRUGS, v.35, no.1, pp 61 - 73 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000599802900001 | - |
dc.identifier.scopusid | 2-s2.0-85097668845 | - |
dc.citation.endPage | 73 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 61 | - |
dc.citation.title | BIODRUGS | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 뉴질랜드 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | COST-EFFECTIVENESS ANALYSIS | - |
dc.subject.keywordPlus | ECONOMIC EVALUATIONS | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | PEMBROLIZUMAB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | ATEZOLIZUMAB | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.